Form 8-K - Current report:
SEC Accession No. 0001641172-25-018553
Filing Date
2025-07-10
Accepted
2025-07-10 13:02:07
Documents
17
Period of Report
2025-07-09
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K form8-k.htm   iXBRL 8-K 53109
2 EX-4.1 ex4-1.htm EX-4.1 130410
3 EX-10.1 ex10-1.htm EX-10.1 83444
4 EX-99.1 ex99-1.htm EX-99.1 13597
5 GRAPHIC ex99-1_001.jpg GRAPHIC 14799
  Complete submission text file 0001641172-25-018553.txt   523911

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE cldi-20250709.xsd EX-101.SCH 3017
7 XBRL LABEL FILE cldi-20250709_lab.xml EX-101.LAB 34239
8 XBRL PRESENTATION FILE cldi-20250709_pre.xml EX-101.PRE 22360
20 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3825
Mailing Address 4475 EXECUTIVE DRIVE SUITE 200 SAN DIEGO CA 92121
Business Address 4475 EXECUTIVE DRIVE SUITE 200 SAN DIEGO CA 92121 858-794-9600
Calidi Biotherapeutics, Inc. (Filer) CIK: 0001855485 (see all company filings)

EIN.: 862967193 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40789 | Film No.: 251115638
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)